Skip to content
DraconiticResearch
Search Sources API
182,544 studies31 sourcesUpdated 12 min ago
Peer-reviewedCC BYBiomedicines

Oxytocin Signalling in Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia and Overactive Bladder Syndrome: A Narrative Review

  • Masroor Badshah1
  • Jibriil Ibrahim2
  • Khaled A. Elnahriry3
  • Ralf Middendorff4
  • Michael Whittaker2
  • Betty Exintaris2
4 affiliations
  1. 1Hudson Institute of Medical Research, , Clayton, VIC 3168, Australia
  2. 2Monash Institute of Pharmaceutical Sciences, , Parkville, VIC 3052, Australia
  3. 3Department of Pharmaceutical Sciences, College of Pharmacy, , Riyadh 11533, Saudi Arabia
  4. 4Institute of Anatomy and Cell Biology, Justus-Liebig-University, 35390 Giessen, Germany
Read full textPDFDOICite

Abstract

Lower urinary tract symptoms (LUTSs) associated with benign prostatic disease and overactive bladder syndrome (OAB) substantially impair quality of life. This narrative review evaluates oxytocin receptor (OXTR) localisation, signalling, and contractile responses in prostate and bladder tissue, with anatomical and pharmacological context restricted to interpretation of these findings. Experimental receptor expression and antagonist responses provide mechanistic plausibility, but species differences, vasopressin receptor cross-reactivity, and inconsistent human tissue responses limit translation. Preclinical effects on tissue contractility and reproductive endpoints are distinguished from clinical urinary outcomes. OXTR antagonism remains investigational for LUTSs and OAB; clinical efficacy and safety require validation. Proposed artificial intelligence applications are limited to experimental receptor localisation, contraction analysis, and phenotyping.

Related

  1. Two-dimensional computational fluid dynamics study of urine flow in the prostatic fossa after benign prostatic hyperplasia surgery: a single-patient model
    Huanrui Wang, Weiyu Zhang, Zehua Ding +2
    Translational andrology and urologyPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  2. Intake of foods containing phytochemicals is correlated with benign prostatic hyperplasia development: a long-term follow-up study
    Tomiyo Nakamura, Akiko Shiotani, Chikako Yasui +2
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textGeneral medicineCrossref
  3. Cumulative average glucose–lipid metabolic obesity index associates with benign prostatic hyperplasia incidence in Chinese middle-aged and older men
    Juan Zhou, Jianyun Xie, Bo Zheng +5
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textGeneral medicineCrossref
  4. Holmium laser enucleation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia
    Niranjan Sathianathen, Eu Chang Hwang, Sarah Jane Brown +4
    The Cochrane Database of Systematic ReviewsPeer-reviewedPublisher termsFull textGeneral medicinePMC
  5. Minimally invasive vs standard surgical treatment: A systematic review comparing prostatic artery embolization and transurethral resection of the prostate for benign prostatic hyperplasia.
    Hubert Konieczny, Bartosz Żabicki, Konrad Suchora +1
    Central European journal of urologyPeer-reviewedCC BY-NC-SAFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{badshah2026oxytocin,
  title = {{Oxytocin Signalling in Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia and Overactive Bladder Syndrome: A Narrative Review}},
  author = {Masroor Badshah and Jibriil Ibrahim and Khaled A. Elnahriry and Ralf Middendorff and Michael Whittaker and Betty Exintaris},
  journal = {Biomedicines},
  year = {2026},
  month = oct,
  doi = {10.3390/biomedicines14102306},
  url = {https://europepmc.org/article/PMC/PMC13702364},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Oxytocin Signalling in Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia and Overactive Bladder Syndrome: A Narrative Review
AU  - Masroor Badshah
AU  - Jibriil Ibrahim
AU  - Khaled A. Elnahriry
AU  - Ralf Middendorff
AU  - Michael Whittaker
AU  - Betty Exintaris
PY  - 2026
DA  - 2026/10/01
JO  - Biomedicines
DO  - 10.3390/biomedicines14102306
UR  - https://europepmc.org/article/PMC/PMC13702364
AB  - Lower urinary tract symptoms (LUTSs) associated with benign prostatic disease and overactive bladder syndrome (OAB) substantially impair quality of life. This narrative review evaluates oxytocin receptor (OXTR) localisation, signalling, and contractile responses in prostate and bladder tissue, with anatomical and pharmacological context restricted to interpretation of these findings. Experimental receptor expression and antagonist responses provide mechanistic plausibility, but species differences, vasopressin receptor cross-reactivity, and inconsistent human tissue responses limit translation. Preclinical effects on tissue contractility and reproductive endpoints are distinguished from clinical urinary outcomes. OXTR antagonism remains investigational for LUTSs and OAB; clinical efficacy and safety require validation. Proposed artificial intelligence applications are limited to experimental receptor localisation, contraction analysis, and phenotyping.
SN  - 2227-9059
ER  -